Home About us Contact
|
Home About us Contact | ||
|
|
||
Aneurysm Expansion (aneurysm + expansion)
Selected AbstractsLeft Coronary Artery Compression Caused by a False Aneurysm Expansion after Perforation of Type A Aortic DissectionJOURNAL OF CARDIAC SURGERY, Issue 1 2010Jan Vojacek M.D., Ph.D. (J Card Surg 2010;25:72-73) [source] A Giant Dissecting Aneurysm of Ascending AortaECHOCARDIOGRAPHY, Issue 3 2005Oben Baysan M.D. Aortic aneurysm is a serious clinical challenge for the cardiologist. Aneurysm expansion frequently associated with significant dissection and rupture risk. Currently available diagnostic modalities make earlier diagnosis and therapy possible hence giant aneurysm with dissection is relatively rare. In this case report, we present a patient with giant aortic aneurysm with dissection. [source] Review of Interventional Repair for Abdominal Aortic AneurysmJOURNAL OF INTERVENTIONAL CARDIOLOGY, Issue 6 2006F.A.C.C., F.A.C.P., F.A.S.A., MAJED CHANE M.D. Abdominal aortic aneurysm is associated with high mortality rate. For over 50 years, open surgical repair was the standard approach for large aneurysms. However, over the past decade, endovascular aneurysm repair (EVAR) has emerged as a viable alternative. EVAR is associated with lower operative and short-term morbidity and mortality and similar long-term survival (up to 4 years) compared with surgical repair. Endoleak remains a significant limitation associated with aneurysm expansion and reintervention. With newer, more versatile endograft designs, improvements in durability, and better surveillance techniques, the utilization of EVAR is likely to continue to expand. [source] Genotype,phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansionBRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue 11 2005P. Eriksson Background: The aim of the study was to investigate the effect of functional polymorphisms in promoters of matrix metalloproteinase (MMP) 2, MMP-3, MMP-9, MMP-12 and plasminogen activator inhibitor (PAI) 1 genes on the growth rate of small abdominal aortic aneurysms (AAA). Methods: Some 455 individuals with a small AAA (4·0,5·5 cm) were monitored for aneurysm growth by ultrasonography (mean follow-up 2·6 years). They also provided a DNA sample for analysis of the ,1306 C > T, ,1171 5A > 6A, ,1562 C > T, ,82 A > G and ,675 4G > 5G alleles of MMP-2, MMP-3, MMP-9, MMP-12 and PAI-1, respectively. Mean linear AAA growth rates were calculated by flexible modelling; the sample size was sufficient to detect variants that influenced the growth rate by 25 per cent. Results: For MMP-2, MMP-9 and MMP-12 genotypes, growth rates were similar to the mean linear growth rate of 3·08 mm per year. For MMP-3, growth rates were 3·05 (for 5A5A), 3·19 (for 5A6A) and 2·90 (for 6A6A) mm per year. For PAI-1, patients with 4G4G, 4G5G and 5G5G genotypes had growth rates of 3·18, 2·92 and 3·47 mm per year, respectively, for aneurysms with a baseline diameter of 45·1, 44·6 and 46·2 mm. The increased growth rate for patients with PAI-1 5G5G genotype was not statistically significant (P = 0·061), although these patients had the lowest plasma PAI-1 concentrations (P = 0·018). Conclusion: There was no evidence that any specific MMP polymorphism had a clinically significant effect on AAA expansion. The plasminogen system may have a small but clinically significant role in AAA development. Much larger studies would be needed to evaluate genes of smaller effect. Copyright © 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. [source] Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion (Br J Surg 2001: 88: 1066,72)BRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue 1 2002Article first published online: 5 NOV 200 Tho original article to which this Corrigendum refers was published in British Journal of Surgery 2001: 88: 1066,72) The revised abstract is included below. Background:, Macrolide treatment has been reported to lower the risk of recurrent ischaemic heart disease. The influence of macrolides on the expansion rate of abdominal aortic aneurysms (AAAs) remains unknown. The aim was to investigate the effect of roxithromycin on the expansion rate of small AAAs. Methods:, A total of 92 subjects with a small AAA were recruited from two populations. One population consisted of 6339 men aged 65,73 years who were offered a hospital-based mass screening programme for AAA. From this population 66 subjects were recruited. The remaining 26 men were recruited from among 49 subjects diagnosed at interval screening for an initial aortic diameter between 25 and 29 mm. Subjects were randomized to receive either oral roxithromycin 300 mg once daily for 28 days or matching placebo, and followed for a mean of 1·5 years. Results:, During the first yearthe mean annual expansion rate of AAAs was reduced by 44 per cent in the intervention group (1·56 mm per year), compared with 2·80 mm per year following placebo (P = 0·02). During the second year the difference was only 5 per cent. Multiple linear regression analysis showed that roxithromycin treatment and initial AAA size were significantly related to AAA expansion when adjusted for smoking, diastolic blood pressure and immunoglobulin A level of 20 or more. Logistic regression analysis confirmed a significant difference in expansion rates above 2 mm annually between the intervention and placebo groups: odds ratio = 0·09 (95 per cent confidence interval 0·01,0·83). Conclusion:, In comparison to placebo, roxithromycin 300 mg daily for 4 weeks reduced the expansion rate of AAAs. © 2002 British Journal of Surgery Society Ltd [source] | ||||||||||